Related Experiment Video
Updated: Jun 22, 2026
07:49
Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
Published on: September 17, 2014
12.0K
Buccal Transmucosal Controlled Drug Delivery System: Emerging Strategy For Oral Antidiabetic Therapy - A Review
Pragati Kumar1, Akanksha Singh Tomar1, Ashwani Gupta1
1PSIT-Pranveer Singh Institute of Technology (Pharmacy), Bhauti Kanpur, Uttar Pradesh, India.
Current Drug Safety
|March 21, 2026
Summary
Buccal drug delivery offers a promising alternative for diabetes treatment, improving medication absorption and patient convenience. This method bypasses common oral drug limitations, enhancing therapeutic outcomes for conditions like diabetes mellitus.
Area of Science:
- Pharmacology and Pharmaceutics
- Biomedical Engineering
- Endocrinology
Background:
- Standard oral diabetes medications face challenges including poor absorption, hepatic first-pass metabolism, and poor patient compliance.
- Buccal drug delivery presents an alternative route, utilizing the oral mucosa for systemic drug absorption.
- Gastrointestinal side effects from oral antidiabetics like metformin and alpha-glucosidase inhibitors can impede treatment adherence.
Purpose of the Study:
- To review the potential of buccal drug delivery systems for managing diabetes mellitus.
- To analyze the anatomical and physiological characteristics of the buccal mucosa relevant to drug absorption.
- To explore various buccal delivery systems and strategies for enhancing drug permeation.
Main Methods:
- Comprehensive literature review of buccal mucosa structure, function, and drug absorption.
- Analysis of different buccal dosage forms (tablets, films, gels, patches) and permeation enhancers.
- Examination of the pharmacokinetic and clinical implications of buccal delivery for antidiabetic drugs (e.g., Metformin, Glibenclamide).
Main Results:
- Buccal delivery offers controlled release and avoids hepatic first-pass metabolism, potentially improving bioavailability of diabetes medications.
- Various delivery systems and permeation enhancement techniques are available for buccal administration.
- While convenient, buccal delivery has limitations including poor absorption, salivary washout, and limited surface area.
Conclusions:
- Buccal drug delivery is a viable and convenient alternative for diabetes treatment, potentially overcoming limitations of oral administration.
- Further research and technological advancements are needed to optimize buccal systems and address existing challenges for wider clinical application.
- This delivery route holds potential to improve patient compliance and therapeutic efficacy for managing diabetes mellitus.
Keywords:
Buccal drug deliverybioavailabilitycontrolled drug releasefirst-pass metabolismmetforminmucoadhesive polymersoral antidiabetic drugspermeation enhancers.More Related Videos
09:31Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
7.7K
04:09Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing
Published on: December 13, 2024
1.5K
Related Concept Videos
01:18Drug Delivery: Enteral Route
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
Drugs in...
Drugs in...
01:23Oral Drug Delivery Systems: Introduction
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...